Teva and Active Biotech are also looking to bring their new MS treatment Laquinimod to the market for 2012. The drug is forecast to be making $600 million in peak annual sales, but received a blow when a recent Phase III trial showed that it failed to reduce relapse rates in MS patients compared to placebo.
Teva is looking to the drug as a successor to its current injectable MS drug Copaxone (glatiramer acetate), which made the firm $3.3 billion last year.
http://www.inpharm.com/news/171690/major-new-drugs-2012
Scrolla ner på sidan så får du ovan skrivna text.
Aktien kommer inte att stanna vid 170 SEK
– 300 SEK är mer tänkbart…
Jag kan bara säga: KÖP!
Mvh
M.